focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.10
Ask: 3.40
Change: -0.10 (-2.99%)
Spread: 0.30 (9.677%)
Open: 3.35
High: 3.35
Low: 3.25
Prev. Close: 3.35
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK shareholder meetings calendar - next 7 days

Fri, 01st Mar 2024 15:49

Monday 4 March 
Ascent Resources PLCGM re bonus issue of preference shares
JPMorgan Emerging Europe, Middle East & Africa Securities PLCAGM
Lexington Gold LtdAGM
Tuesday 5 March 
Ajax Resources PLCGM re extension of investment mandate
Beowulf Mining PLCGM re capital raise
CC Japan Income & Growth Trust PLCAGM
Driver Group PLCAGM
Edinburgh Worldwide Investment Trust PLCAGM
Jersey Electricity PLCAGM
Wednesday 6 March 
Ecofin Global Utilities & Infrastructure Trust PLCAGM
Mila Resources PLCAGM
Paragon Banking Group PLCAGM
Thursday 7 March 
Asia Strategic Holdings LtdAGM
CT UK Capital & Income Investment Trust PLCAGM
Henderson Opportunities Trust PLCAGM
XPS Pensions Group PLCGM re directors' remuneration policy 2024
Friday 8 March 
Allergy Therapeutics PLCAGM
All Things Considered Group PLCAGM
Chenavari Toro Income Fund LtdAGM
Neo Energy Metals PLCAGM
Schroder UK Mid Cap Fund PLCAGM
Silverwood Brands PLCGM re proposed share capital reduction
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
26 Oct 2020 14:17

IN BRIEF: Allergy Therapeutics Kicks Off Grass Allergy Therapy Study

IN BRIEF: Allergy Therapeutics Kicks Off Grass Allergy Therapy Study

Read more
26 Oct 2020 13:37

Allergy Therapeutics screens first patients in grass pollen study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the screening of the first patient in its exploratory field study 'G309', to evaluate the efficacy and safety of 'Grass MATA MPL' in subjects with seasonal allergic rhinitis or rhinoconjunctivitis induced by grass pollen exposure.

Read more
23 Sep 2020 14:02

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

Read more
4 Sep 2020 19:39

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

Read more
3 Sep 2020 15:31

Allergy Therapeutics signs new vaccine deal with Saliba and DeepVax

(Sharecast News) - Biotechnology company Allergy Therapeutics announced further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field on Thursday.

Read more
15 Jul 2020 11:47

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

Read more
15 Jul 2020 09:03

Allergy Therapeutics revenues grow despite Covid-19 disruption

(Sharecast News) - Biotechnology company Allergy Therapeutics reported a "strong" full-year performance on Wednesday despite challenges stemming from the Covid-19 pandemic.

Read more
9 Jul 2020 21:19

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

Read more
9 Jul 2020 16:26

Allergy Therapeutics pleased with invalidation of B301 trial data

(Sharecast News) - Biotechnology company Allergy Therapeutics announced the outcome of scientific advice from the German Regulatory Authority, the Paul Ehrlich Institute (PEI), over invalidation of the primary endpoint data of the Birch MATA MPL pivotal phase 3 clinical trial, or 'B301', on Thursday.

Read more
24 Jun 2020 11:53

Allergy Therapeutics Anticipates Profit Ahead Of Expectations

Allergy Therapeutics Anticipates Profit Ahead Of Expectations

Read more
24 Jun 2020 10:12

Allergy Therapeutics on track to 'significantly' exceed FY expectations

(Sharecast News) - Biotechnology company Allergy Therapeutics said on Wednesday that its 2020 trading performance was on track to exceed market expectations.

Read more
4 Mar 2020 10:46

Allergy Therapeutics Well-Placed Despite Regulatory "Challenge"

Allergy Therapeutics Well-Placed Despite Regulatory "Challenge"

Read more
26 Feb 2020 16:15

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
16 Jan 2020 13:28

Allergy Therapeutics Outlook Confident As Revenue Rises In First Half

Allergy Therapeutics Outlook Confident As Revenue Rises In First Half

Read more
26 Nov 2019 14:15

Allergy Therapeutics to take 'stepwise approach' to upcoming grass study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market on its grass MATA MPL phase 3 study, due to start in autumn 2020, on Tuesday, reporting that following further investigation of the phase 3 birch MATA MPL study, the upcoming grass study would now take a 'stepwise approach'.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.